On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Shares of Viking ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Weight loss injections can help people lose more weight than with other methods of weight loss, including lifestyle changes ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

The mass rollout of weight loss injections on the NHS in England began in June. It means GPs are allowed to prescribe the drugs for the first time. Around 220,000 people are expected to receive ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today.

Weight-loss injections are dominating the market: Where will GLP-1 pills fit in? Glucagon-like peptide-1 (GLP-1) medications have emerged as powerful tools for weight loss. So far, injectable ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential By Nick Paul Taylor Jun 23, 2025 4:29am Novo Nordisk obesity drugs GLP-1 Clinical Data ...